This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
LG Chem will receive totaling up to $95.5 million for the China rights
Patients receiving Polivy plus R-CHP for DLBCL reported similar health-related quality of life outcomes
The IPO is a complete OFS by existing shareholder Helix Investment Holdings
Antibody levels remained above baseline six months after completion of a three-dose (Month 0-2-6) or a two-dose (Month 0-6) vaccination schedule
Phase-III trials were conducted for safety, and immunogenicity in around 3,100 subjects, in 14 trial sites across India (supported by BIRAC)
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
To fund the upfront payment, Biocon Biologics has secured USD 1.2 billion of Sustainability Linked Loan
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
Ties up with Denmark’s Vestfrost Solutions, to cater to the unique needs of the Indian market
Subscribe To Our Newsletter & Stay Updated
